A. Li's Profile

Role	Title	Level	Year	L/R
🐜	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium 128 auth. P. Grivas, A. Khaki, T. Wise-Draper, B. French, C. Hennessy, C.‐Y. Hsu, Y. Shyr, X. Li, T. Choueiri, C. Painter, S. Peters, B. Rini, M. Thompson, S. Mishra, D. Rivera, ... J. Acoba, M. Abidi, Z. Bakouny, B. Bashir, T. Bekaii-Saab, S. Berg, E. Bernicker, M. Bilen, P. Bindal, R. Bishnoi, N. Bouganim, D. Bowles, A. Cabal, P. Caimi, D. Chism, J. Crowell, C. Curran, A. Desai, B. Dixon, D. Doroshow, E. Durbin, A. Elkrief, D. Farmakiotis, A. Fazio, L. Fecher, D. Flora, C. Friese, Jun Fu, S. Gadgeel, M. Galsky, D. Gill, M. Glover, S. Goyal, P. Grover, S. Gulati, S. Gupta, S. Halabi, T. Halfdanarson, B. Halmos, D. Hausrath, J. Hawley, E. Hsu, M. Huynh-Le, C. Hwang, C. Jani, A. Jayaraj, D.B. Johnson, A. Kasi, H. Khan, V. Koshkin, N. Kuderer, D. Kwon, P. Lammers, A. Li, A. Loaiza-Bonilla, C. Low, M. Lustberg, G. Lyman, R. McKay, C. McNair, H. Menon, R. Mesa, V. Mico, D. Mundt, G. Nagaraj, E. Nakasone, J. Nakayama, A. Nizam, N. Nock, C. Park, J. Patel, K. Patel, P. Peddi, N. Pennell, A. Piper-Vallillo, M. Puc, D. Ravindranathan, M. Reeves, D. Reuben, L. Rosenstein, R. Rosovsky, S. Rubinstein, M. Salazar, A. Schmidt, G. Schwartz, M. Shah, S. Shah, C. Shah, J. Shaya, S. Singh, M. Smits, K. Stockerl-Goldstein, D. Stover, M. Streckfuss, S. Subbiah, L. Tachiki, E. Tadesse, A. Thakkar, M. Tucker, A. Verma, D. Vinh, M. Weiss, J.T. Wu, E. Wulff-Burchfield, Z. Xie, P. Yu, T. Zhang, A. Zhou, H. Zhu, L. Zubiri, D. Shah, J. Warner, G. Lopes	8	2021	8 🐜
🐜	P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients 16 auth. R. Juergens, Q. Chu, J. Rothenstein, F. D. Angelis, S. Banerji, K. Marquis, D. Sauciuc, P. Bégin, N. Finn, V. Hirsh, ... A. Faghih, J. Yun, A. Li, A. Acevedo, L. Musallam, P. Cheema	4	2017	4 🐜
🐜	1102PRESULTS OF THE EXTENSION TRIAL OF OPTIM, A MULTICENTER, RANDOMIZED PHASE 3 TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) VS GM-CSF FOR UNRESECTED STAGE IIIB-IV MELANOMA. 15 auth. J. Nemunaitis, R. Andtbacka, M. Ross, T. Amatruda, J. Chesney, F. Collichio, K. Harrington, N. Steven, S. Fourie, L. Dreosti, ... A. Li, K. Liu, M. Shilkrut, R. Coffin, H. Kaufman	2	2014	2 🐜
🐜	1129TiPA PHASE 1B/2, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TALIMOGENE LAHERPAREPVEC (T-VEC) AND IPILIMUMAB (IPI) VERSUS IPI ALONE IN PREVIOUSLY UNTREATED, UNRESECTED, STAGE IIIB, IIIC, AND IV MELANOMA. 16 auth. F. Collichio, M. Milhem, R. Andtbacka, I. Puzanov, Y. Saenger, J. Chesney, L. Cranmer, O. Hamid, T. Logan, J. Glaspy, ... C. Lebbé, C. Garbe, J. Gansert, A. Li, J. Chou, H. Kaufman	2	2014	2 🐜
🐬	Prostate cancer profile and risk stratification of patients treated at Universitas Annex Department of Oncology, Bloemfontein, Free State, during 2008 to 2010 Alicia Sherriff, N. D. Costa, A. Engelbrecht, A. Li, N. Price, Gina Joubert	2	2015	2 🐬
🐜	193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment. 7 auth. E. Felip, J. V. van Meerbeeck, J. Wolf, A. Ardizzoni, A. Li, S. Srinivasan, ... S. Popat	2	2016	2 🐜
🦁	198PTARGETING DE NOVO C-MET OVEREXPRESSION IN ADVANCED NON- SMALL-CELL LUNG CANCER. A. Li, J. Yang, X. Zhang, Q. Zhou, Y. Wu	1	2014	1 🦁
🐜	SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis 15 auth. M. Javle, S. Sadeghi, S. Roychowdhury, A. El-Khoueiry, L. Goyal, P. Philip, R. Kelley, I. Borbath, T. Macarulla, W. Yong, ... S. Tanasanvimon, A. Li, M. Howland, A. Pande, G. Abou-Alfa	1	2020	1 🐜